ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Arrhythmia-induced cardiomyopathy

Arrhythmia-induced cardiomyopathy
Author:
Cynthia M Tracy, MD
Section Editor:
William J McKenna, MD
Deputy Editor:
Todd F Dardas, MD, MS
Literature review current through: Jan 2024.
This topic last updated: May 24, 2022.

INTRODUCTION — Cardiomyopathies are diseases of the heart muscle, inclusive of a variety of myocardial disorders that manifest with various structural and functional phenotypes and are frequently genetic. Although some have defined cardiomyopathy to include myocardial disease caused by known cardiovascular causes (such as hypertension, ischemic heart disease, or valvular disease), current major society definitions of cardiomyopathy exclude heart disease secondary to such cardiovascular disorders [1,2]. (See "Definition and classification of the cardiomyopathies" and "Causes of dilated cardiomyopathy".)

The prognosis in patients with dilated cardiomyopathy is variable and dependent on the cause; importantly, there are some etiologies that may improve or resolve following treatment. One such cause is an arrhythmia-induced cardiomyopathy (also known as tachycardia-induced cardiomyopathy, tachycardia-mediated cardiomyopathy, and tachymyopathy), a relatively rare though well-recognized entity caused by long-standing tachycardia, which in most instances is readily treatable with a good prognosis [3]. Arrhythmia-induced cardiomyopathy has been reported with nearly all types of tachyarrhythmias and frequent ectopy, both supraventricular and ventricular [4].

A common clinical problem is determining whether the tachycardia is the primary cause of the patient's cardiomyopathy, or if the tachycardia is secondary to a cardiomyopathy of different etiology. This topic will discuss arrhythmia-induced cardiomyopathy as a primary cause of cardiomyopathy. Arrhythmias occurring in the setting of a specific cardiomyopathy are discussed separately. (See "Hypertrophic cardiomyopathy in adults: Supraventricular tachycardias including atrial fibrillation" and "Hypertrophic cardiomyopathy: Risk stratification for sudden cardiac death" and "Arrhythmogenic right ventricular cardiomyopathy: Anatomy, histology, and clinical manifestations", section on 'Ventricular arrhythmias'.)

EPIDEMIOLOGY — While the exact incidence of arrhythmia-induced cardiomyopathy remains unclear, an association between tachycardia and cardiomyopathy has been recognized for some time [5-8]. Virtually every form of supraventricular tachyarrhythmia, including ectopic atrial tachycardia (AT), nonparoxysmal junctional tachycardia, and atrial fibrillation (AF), has been associated with reversible left ventricular (LV) dysfunction or "cardiomyopathy." The development of a cardiomyopathy has also been documented with ventricular tachyarrhythmias and frequent ectopic beats [9-11]. (See "Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm" and 'Frequent ectopic beats' below.)

Some insight into the prevalence of arrhythmia-induced cardiomyopathy can be derived from cohort studies of patients undergoing catheter ablation for symptomatic arrhythmias. As examples:

●Among a cohort of 331 patients who were referred for catheter ablation of incessant AT, myocardial dysfunction was present in 9 percent of patients [12]. Patients with an arrhythmia-induced cardiomyopathy were younger (mean age 39 versus 51 years), more frequently male (60 versus 38 percent), and had incessant or very frequent paroxysmal tachycardia (100 versus 20 percent).

●Among a cohort of 625 patients undergoing catheter ablation for a variety of tachyarrhythmias, a tachycardia-induced cardiomyopathy was present in 2.7 percent (17 of 625 patients) [13].

●Among a cohort of 1269 patients undergoing ablation for atrial flutter, 184 had reduced LV ejection fraction (LVEF; <40 percent) at baseline [14].

PATHOPHYSIOLOGY — Chronic tachycardia ultimately produces significant cardiac structural changes, including LV dilation and cellular morphologic changes [15-19]. However, the exact mechanism by which tachycardia produces these changes is not well defined.

Animal models, initially developed in the general investigation of heart failure (HF), have been studied extensively in the evaluation of arrhythmia-induced cardiomyopathy. Rapid pacing produces changes in animals that are similar to those observed in humans, including a marked depression of LVEF, elevated filling pressures, depressed cardiac output, and increased systemic vascular resistance [16-18,20-24]. These changes are generally reversible with cessation of the tachycardia, although in some cases LVEF may not return to baseline [24,25]. Similar findings have been reported in an animal model following the delivery of premature ventricular complexes/contractions (PVCs; also referred to as premature ventricular beats or premature ventricular depolarizations) in a bigeminal pattern for 12 weeks, which resulted in LV dilation and reduction in LVEF [26].

The morphologic and biochemical changes that result from an arrhythmia-induced cardiomyopathy also may produce electrophysiologic abnormalities. In a canine model, chronic tachycardia was associated with ventricular arrhythmias (including polymorphic ventricular tachycardia [VT] and sudden death) that result from a prolongation in repolarization [27].

Many alterations in neurohumoral and cellular activation have been described, and several factors probably contribute to the development of rate-related myocardial dysfunction. Although data supporting certain potential mechanisms are compelling, it remains unclear whether they play an etiologic role or if they arise as a consequence of tachycardia.

●Depletion of myocardial energy stores and myocardial ischemia – Studies in animal models have shown that persistent tachycardia depletes high-energy stores as evidenced by reduced myocardial levels of creatine, phosphocreatine, and adenosine triphosphate (ATP), and diminished activity of the Na-K-ATPase pump [28-30]. These changes are probably due to alterations in cellular metabolism with mitochondrial injury and increased activity of Krebs cycle oxidative enzymes [15,20].

Myocardial ischemia may play a role in the development of arrhythmia-induced cardiomyopathy. Similar depletions in high-energy stores are seen in ischemic models following vessel occlusion, situations where high-energy stores are rapidly depleted and LV dysfunction occurs [31,32]. High-energy stores return to normal within days after the ischemic insults. Tachycardia-induced depletion of high-energy stores, which may be mediated in part by ischemia, is reversible and may explain the reversibility of this cardiomyopathy.

Abnormalities in subendocardial to subepicardial flow ratios and impaired coronary flow have been found in arrhythmia-induced cardiomyopathy [33-36]. The impaired coronary blood flow occurs in association with elevation in cardiac filling pressures and impaired LV diastolic function [25,37,38].

●Abnormal calcium handling and beta adrenergic responsiveness – Abnormalities in both calcium channel activity and sarcoplasmic reticulum calcium transport may contribute to the myocardial dysfunction in arrhythmia-induced cardiomyopathy [20,35]. Diminished beta-adrenergic responsiveness has also been described and may be due to reduced myocyte beta-1 receptor density (downregulation) [37,39,40]. The reduction in beta receptor density and responsiveness is independent of hemodynamic and neurohumoral factors [41].

●Oxidative stress and injury – In patients with AF and atrial dysfunction, there is histologic evidence of oxidative stress and injury in the atrial myocardium [42]. This results in peroxynitrite formation, which modifies myofibrillar proteins, contributes to loss of fibrillar protein function, and alters myofibrillar energetics.

Support for the role of oxidative stress comes from one animal study which found that the administration of the antioxidant vitamins E, C, and beta-carotene attenuated the cardiac dysfunction and prevented beta receptor downregulation produced by rapid cardiac pacing [43].

●Genetic basis and ACE gene polymorphism – An association has been reported between a gene polymorphism and arrhythmia-induced cardiomyopathy. Levels of angiotensin converting enzyme (ACE) are associated with a 287 base pair insertion (I)/deletion (D) polymorphism in intron 16 of the ACE gene. The DD genotype is associated with increased serum ACE levels and a higher incidence of both ischemic and idiopathic dilated cardiomyopathy. In a study comparing 20 patients with arrhythmia-induced cardiomyopathy, 20 controls with persistent tachycardia but normal LV function, and 24 normal volunteers, the DD genotype was significantly more common in the patients with arrhythmia-induced cardiomyopathy [44].

●Histopathologic and immunologic findings – Among a cohort of 189 patients with new onset HF and reduced LVEF not related to valvular or ischemic heart disease, 19 patients met criteria for tachycardia-induced cardiomyopathy. Endomyocardial biopsies in the tachycardia-induced cardiomyopathy patients showed a stronger myocardial expression of major histocompatibility complex class II molecule and enhanced infiltration of CD68+ macrophages compared with patients with idiopathic dilated cardiomyopathy. Compared to patients with ischemic cardiomyopathy, those with tachycardia induced cardiomyopathy had fewer T cells and macrophages. Fibrosis was also less prominent in the tachycardia induced cardiomyopathy patients. However, electron microscopy in these patients showed abnormal mitochondrial distribution and enhanced myocyte size. RNA expression analysis showed alterations in metabolic pathways [45].

ARRHYTHMIAS ASSOCIATED WITH ARRHYTHMIA-INDUCED CARDIOMYOPATHY — A number of tachyarrhythmias have been associated with arrhythmia-induced cardiomyopathy, including AF, atrial flutter, atrial tachycardia (AT), reentrant supraventricular tachycardias, and VT [11,46-60]. In addition, very frequent ectopic beats, both atrial and ventricular, have been associated with arrhythmia-induced cardiomyopathy. Regardless of the arrhythmia, therapy to restore normal sinus rhythm or to slow the ventricular rate (or eliminate ectopy) appears to result in an improvement in LV function (table 1). However, most descriptive series include only a small number of patients.

Supraventricular arrhythmias

Atrial fibrillation and atrial flutter — Epidemiologic studies have shown that patients with AF are at increased risk for HF [61]. In some patients, restoration of sinus rhythm or control of the rapid ventricular rate markedly improves or even normalizes the LVEF, indicating that the LV dysfunction was primarily due to the rapid AF rather than another etiology. Improvement in LV function is seen with both rhythm and rate control, although it may be more likely with rhythm control. (See "Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm".)

There is an association between HF and AF, and it is often not possible to determine which is causative. Nevertheless, an estimated 25 to 50 percent of patients with LV dysfunction and AF have some component of arrhythmia-induced cardiomyopathy [4,62-64].

There are less data on the frequency and predictors of arrhythmia-induced cardiomyopathy in patients with atrial flutter. In one study of patients undergoing ablation for atrial flutter, 25 percent had evidence for cardiomyopathy prior to ablation [65]. Of these, 57 percent had significant improvement in their LVEF postablation. The only predictor of reversibility of cardiomyopathy in this study was average heart rate. Similarly, in a cohort of 1269 patients undergoing ablation for atrial flutter, 184 had reduced LVEF (<40 percent) at baseline. Of these patients with reduced LVEF, 103 patients (56 percent) had marked improvement in LVEF at six months. Those who experienced improvement in the LVEF had similar survival to patients who did not have baseline depressed LVEF. Those whose LVEF failed to improve had a three-fold higher mortality [14].

Atrial tachycardia — Incessant AT, an infrequent cause of symptomatic supraventricular tachyarrhythmia, can cause myocardial dysfunction in approximately 10 percent of patients [12]. Children are more likely than adults to present with arrhythmia-induced cardiomyopathy due to incessant AT. When AT is seen in adults, it is more commonly associated with another cardiac problem, and distinguishing the effect of tachycardia from that of the underlying cardiac disease may be difficult. (See "Focal atrial tachycardia", section on 'Incessant AT resulting in cardiomyopathy' and "Atrial tachyarrhythmias in children", section on 'Focal atrial tachycardia'.)

Incessant AT and ectopic AT have been associated with the development of cardiomyopathy that can be reversed with restoration of sinus rhythm [46-52]. Improved techniques for catheter ablation frequently permit definitive therapy for AT, which can lead to the resolution of myocardial dysfunction with a high degree of success [12,46,52]. (See "Focal atrial tachycardia", section on 'Treatment of incessant AT'.)

Reentrant supraventricular tachycardias — Reentrant supraventricular tachycardias, including atrioventricular nodal reentrant tachycardia (AVNRT) and atrioventricular reciprocating tachycardia (AVRT), are more commonly paroxysmal but can cause a persistent tachycardia. Cases of arrhythmia-induced cardiomyopathy have been described with persistent junctional reciprocating tachycardia, accessory pathway mediated tachycardia (ie, AVRT) and AVNRT [50,54-57]. In the absence of other factors, the cardiomyopathy related to an incessant reentrant supraventricular tachycardia is reversible following catheter ablation [55]. (See "Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway" and "Atrioventricular nodal reentrant tachycardia".)

Ventricular arrhythmias — Only rare reports have described reversible cardiomyopathy related to VT, since this arrhythmia is usually associated with some form of underlying structural heart disease. However, idiopathic LV tachycardia or right ventricular outflow tract VT can arise in structurally normal hearts [9,10,54]. In rare cases, these arrhythmias are persistent or repetitive enough to result in a cardiomyopathy. In one study of patients with repetitive monomorphic VT and/or premature ventricular complexes/contractions (PVCs), an arrhythmia-induced cardiomyopathy was seen in 9 percent, all of which improved with treatment [66]. Similar to supraventricular arrhythmias, the myopathy usually reverses following ablation of the arrhythmia [58]. (See "Ventricular tachycardia in the absence of apparent structural heart disease".)

Unlike monomorphic VT, which can be present and hemodynamically stable for extended periods of time, polymorphic VT, which is generally an unstable rhythm, and ventricular fibrillation, a non-perfusing rhythm, are not associated with arrhythmia-induced cardiomyopathy.

Frequent ectopic beats

Frequent ventricular ectopy — Very frequent ventricular ectopy in the form of PVCs has been associated with a reversible cardiomyopathy, even in the absence of sustained ventricular arrhythmias [11,59,66-74]. While most earlier studies defined "frequent" as greater than 10 percent of overall heartbeats, in contemporary practice a cutoff of >15 percent of all heartbeats is more commonly used. Although some patients with similarly high PVC burdens can maintain normal cardiac function, PVC-induced cardiomyopathy has also been reported in patients with PVC burdens as low as 4 to 5 percent.

●In a prospective observational cohort study of 80 patients (59 percent male, mean age 53 years) with frequent PVCs (mean PVC burden 22 percent) and reduced LVEF (≤50 percent) who underwent catheter ablation, 53 patients (66 percent) had successful long-term elimination of PVCs, with significant improvement in LVEF and New York Heart Association (NYHA) functional class [70].

●In a 2014 systematic review and meta-analysis of radiofrequency ablation for the treatment of idiopathic PVCs originating from the right ventricular outflow tract, catheter ablation was associated with a significant improvement in LVEF, though the meta-analysis was limited by significant heterogeneity among the studies [75]. (See "Premature ventricular complexes: Treatment and prognosis".)

In addition to the overall frequency of PVCs, QRS duration, epicardial site of origin of PVCs, and resulting dyssynchrony all appear to play a role in the development of cardiomyopathy and are associated with outcomes following catheter ablation. Greater dyssynchrony increases the risk of cardiomyopathy, wider QRS complexes appear more likely to result in cardiomyopathy with a lower overall burden of PVCs while also being associated with longer times to normalization of LV systolic function following ablation, and epicardial PVC origin also appears to predict delayed LV function recovery [74,76-80].

Frequent atrial ectopy — Premature atrial complexes (PACs; also referred to as premature atrial beats, premature supraventricular complexes, or premature supraventricular beats) are usually benign, but a high burden of PACs has been associated with a reversible cardiomyopathy [81,82].

CLINICAL PRESENTATION — The clinical presentation of arrhythmia-induced cardiomyopathy is variable but usually involves signs and/or symptoms related to the tachyarrhythmia (eg, palpitations, dyspnea, chest discomfort, etc), HF (eg, dyspnea, edema, weight gain, orthopnea, etc), or both. In our experience, HF symptoms are more common since patients with symptomatic tachyarrhythmias will frequently seek medical attention earlier in the course of their care and prior to the development of a cardiomyopathy. The approach to the patient with suspected arrhythmia-induced cardiomyopathy includes a thorough history and physical examination, with appropriately selected tests to establish the diagnosis and assess acuity, severity, and etiology. Several professional societies have issued recommendations for the evaluation of patients with suspected HF or cardiomyopathy [83-86].

Signs and symptoms — The clinical presentation of arrhythmia-induced cardiomyopathy is variable but usually involves symptoms of palpitations or HF. Patients may present with palpitations or other symptom (eg, dyspnea, chest discomfort) related to the rapidity or irregularity of their arrhythmia. However, those with more rapid heart rates typically present with symptoms related to the inappropriate heart rate before enough time has elapsed to result in a cardiomyopathy. In contrast, patients with tachycardia but a relatively slower heart rate and no obvious symptoms may have little or no awareness of the arrhythmia. While such patients without palpitations are occasionally discovered during a routine medical exam for other reasons, typically they present with fatigue, decreased exercise tolerance, or symptomatic HF.

Given that patients with more rapid heart rates often present earlier with symptoms related to the tachycardia, some investigators have hypothesized that patients with atrial arrhythmias who subsequently develop arrhythmia-induced cardiomyopathy have slower overall heart rates than patients who do not develop arrhythmia-induced cardiomyopathy. Published reports in both adult and pediatric populations support this hypothesis:

●In a retrospective cohort study of 331 patients who had undergone ablation for atrial tachycardia (AT), among whom 9 percent presented with evidence of arrhythmia-induced cardiomyopathy, those with arrhythmia-induced cardiomyopathy had slower ventricular heart rates during tachycardia compared with patients who did not have arrhythmia-induced cardiomyopathy (120 versus 149 beats per minute) [12]. (See "Focal atrial tachycardia", section on 'Incessant AT resulting in cardiomyopathy'.)

●In a retrospective cohort study of 16 pediatric patients with focal AT, those with AT arising from the atrial appendages were more likely to be asymptomatic at presentation, more likely to have a ventricular heart rate less than 120 beats per minute, and more commonly presented with arrhythmia-induced cardiomyopathy [87].

ECG findings — All patients should have an electrocardiogram (ECG) to document the cardiac rhythm and ventricular heart rate. Whenever possible, obtaining prior ECGs can be extremely helpful to determine whether ambiguous P wave morphologies are related to the sinus node (as seen on prior tracings) versus an ectopic atrial focus. There are no specific ECG findings that distinguish patients with and without arrhythmia-induced cardiomyopathy, and the ECG findings will vary depending upon the underlying tachyarrhythmia. However, by definition, all patients with an arrhythmia-induced cardiomyopathy should have a heart rate greater than 100 beats per minute.

APPROACH TO THE DIAGNOSIS — Arrhythmia-induced cardiomyopathy is defined by the presence of a sustained tachycardia (or frequent episodes of tachycardia or very frequent ectopy) which results in LV systolic dysfunction. Determining which of the pathologies (the arrhythmia or the cardiomyopathy) is the primary pathologic process is key to establishing the diagnosis. Usually the diagnosis of arrhythmia-induced cardiomyopathy can only be made following a successful trial of therapy to slow the ventricular rate or to restore sinus rhythm along with the exclusion of other potential causes of cardiomyopathy.

Patients in whom arrhythmia-induced cardiomyopathy is suspected should undergo continuous cardiac monitoring for 24 to 48 hours and have non-invasive imaging to assess cardiac structure and function. For most patients, a transthoracic echocardiogram is the preferred test for assessing cardiac structure and function due to its widespread availability and ease of performance; however, cardiovascular magnetic resonance (CMR) imaging is a reasonable alternative approach in centers with expertise in this modality.

DIAGNOSTIC TESTING — Once arrhythmia-induced cardiomyopathy is suspected, appropriately selected tests can help to establish the diagnosis. All of the following are performed as part of the initial evaluation.

Cardiac monitoring — Heart rate over time should be continuously measured for 24 to 48 hours using inpatient telemetry or ambulatory (Holter) monitoring to document the average heart rate and, in some cases, provide additional information on the underlying rhythm [88]. A sustained heart rate greater than 100 beats per minute, and particularly greater than 120 beats per minutes, is consistent with arrhythmia-induced cardiomyopathy. Because of the potential reversible nature of arrhythmia-induced cardiomyopathy, if uncertainty persists regarding the cardiac rhythm, full invasive electrophysiologic studies may be necessary to establish the underlying cardiac rhythm and guide the optimal therapy. (See 'Treatment' below and "Invasive diagnostic cardiac electrophysiology studies".)

Assessment of cardiac structure and function — All patients with suspected arrhythmia-induced cardiomyopathy should undergo an assessment of cardiac structure and function to document LV size and function, in particular LVEF. Transthoracic echocardiography is the most common and widespread test for documenting cardiac structure and function, but CMR imaging is an alternative approach. While there are no absolute echocardiographic parameters that can distinguish arrhythmia-induced cardiomyopathy from other forms of dilated cardiomyopathy, in general, the LV end-diastolic dimension tends to be smaller in patients with arrhythmia-induced cardiomyopathy [4,89].

In patients with improved LVEF after treatment of an arrhythmia, CMR may be useful for the evaluation of cardiac structure and function. Patients who have a CMR that demonstrates a low LVEF or late gadolinium enhancement have incomplete resolution of cardiac injury [90]. Alternatively, in assessing the underlying cause of arrhythmia-induced cardiomyopathy, patients in one study with frequent premature ventricular complexes/contractions (PVCs) who failed to improve LVEF after treatment were found to have late gadolinium enhancement on CMR, and likely the cause of the cardiomyopathy was not purely tachycardia mediated [91].

Studies have suggested the use of two-dimensional strain echocardiography as a tool to predict recovery from arrhythmia induced cardiomyopathy [92]. In a study of 71 patients with presumed tachycardia-induced cardiomyopathy, a lower LVEF at baseline and higher relative apical longitudinal strain ratio (RALSR) were associated with no recovery in LVEF during follow-up. However, by multivariate analysis the RALSR was found to be a significant predictor of functional recovery after the arrhythmia was treated.

Excluding other causes of cardiomyopathy — Patients with newly diagnosed HF and/or cardiomyopathy require an assessment for genetic and other causes of LV dysfunction and exclusion of significant underlying coronary heart disease (CHD). Decisions on the initial use of stress testing or coronary angiography should be made based on the presence or absence of symptoms suggestive of CHD and the individual patient's likelihood of CHD. The differential diagnosis of dilated cardiomyopathy, and the approach to excluding CHD, are discussed in greater detail separately. While patients with HF and cardiomyopathies of other etiologies may exhibit rapid heart rates (eg, persistent sinus tachycardia), this can usually be distinguished from an arrhythmia-induced cardiomyopathy by comparison of ECG findings over time (eg, sinus P wave morphology) and response to treatment. An important part of the evaluation is a careful review of the family history, and when the phenotype is clear, genetic testing should be recommended. Several of the genetically determined arrhythmogenic cardiomyopathies can present with frequent ectopy (PVCs, nonsustained VT, and/or AF in association with LV dilation and/or impaired function, eg, desmoplakin, filamin C, lamin AC, desmin) [93,94]. (See "Causes of dilated cardiomyopathy" and "Determining the etiology and severity of heart failure or cardiomyopathy", section on 'Detection of coronary artery disease'.)

TREATMENT — The initial treatments for a patient with HF and suspected arrhythmia-induced cardiomyopathy are the same as those used in most other patients with HF with reduced ejection fraction (eg, angiotensin converting enzyme [ACE] inhibitors or angiotensin II receptor blockers [ARBs], beta blockers, diuretics) and tachyarrhythmias (eg, rate-control medications, consideration of antiarrhythmic drugs and/or cardioversion). However, because of the potentially reversible nature of arrhythmia-induced cardiomyopathy, efforts should be made to achieve adequate ventricular heart rate control or to restore sinus rhythm [4]. Additionally, given the potentially reversible nature of this condition, an adequate trial of therapy is required prior to assessment of the need for cardiac resynchronization therapy or an implantable cardioverter-defibrillator. (See "Cardiac resynchronization therapy in heart failure: Indications and choice of system" and "Primary prevention of sudden cardiac death in patients with cardiomyopathy and heart failure with reduced LVEF" and "Overview of the management of heart failure with reduced ejection fraction in adults", section on 'Pharmacologic therapy'.)

Patients with atrial fibrillation or flutter — For patients in whom AF or atrial flutter is the suspected cause of cardiomyopathy, the initial approach to management is similar to other patients with HF and includes prompt rate control with AV nodal blockers and appropriate anticoagulation. (See "The management of atrial fibrillation in patients with heart failure".)

Beyond these initial steps, controversy still exists as to whether rate control or rhythm control is the optimal therapy for AF- or atrial flutter-induced cardiomyopathy. Our strategy for management is as follows:

●For minimally symptomatic patients with AF in whom adequate rate control is achieved, we continue medical therapy. In patients with a cardiomyopathy whose origin is suspected to be AF or atrial flutter, heart rate control through either rate control or rhythm control can be effective at improving cardiac function [95-98].

●For patients with AF who remain significantly symptomatic or in whom adequate rate control is not achieved with medical therapy alone, we pursue a rhythm control strategy.

●For patients with atrial flutter, rapid ventricular rates, and newly recognized LV systolic function, rate control may be difficult to achieve with medication; in these patients, we perform early electrical cardioversion.

Management of AF and/or atrial flutter is geared towards avoidance of thromboembolic events, reduction of symptoms, and avoidance of arrhythmia-induced cardiomyopathy. Control of heart rate can be met through either a rate control strategy with atrioventricular (AV) nodal blocking agents (or ablation and pacer implant in cases of multiple drug failures) or through maintenance of sinus rhythm (rhythm control strategy). Strategies for rate control versus rhythm control are discussed elsewhere, and choices of agents are dictated by cardiac structure, underlying pathology, and function. (See "Atrial fibrillation: Overview and management of new-onset atrial fibrillation" and "Restoration of sinus rhythm in atrial flutter", section on 'Indications' and "Management of atrial fibrillation: Rhythm control versus rate control".)

At initial presentation of the patient with rapid ventricular rates and newly recognized depressed EF, the concern exists that at least some component is related to arrhythmia-induced cardiomyopathy. This is particularly suspected in younger patients with severe symptoms from the AF. A trial of early cardioversion is warranted in these patients with subsequent monitoring for improvement in cardiac function [99].

Patients with another SVT — For supraventricular tachyarrhythmias (SVTs) other than AF or atrial flutter that result in arrhythmia-induced cardiomyopathy, restoration of sinus rhythm is the usual goal. Options for the restoration of sinus rhythm include electrical cardioversion, antiarrhythmic drugs, and catheter ablation of the arrhythmia. The initial choice of modality will vary depending upon the underlying SVT as well as the local expertise and availability of options (ie, some centers do not perform catheter ablation) but should be made in conjunction with an electrophysiologist experienced in the treatment of sustained tachyarrhythmias.

Certain SVTs are more amenable to electrical cardioversion (eg, atrioventricular nodal reentrant tachycardia), while others are often refractory or recurrent following cardioversion (eg, atrial tachycardia). Often, atrial arrhythmias can be refractory to antiarrhythmics, and AV nodal blocking agents may be required in high doses to achieve appropriate heart rates. In patients with depressed LVEF, it is important to avoid agents that have a higher likelihood of proarrhythmia (eg, flecainide) or that could further depress LVEF (eg, disopyramide). If an ablation is performed, close follow-up is required even after successful ablation because of the tendency for cardiomyopathy to recur if tachycardia recurs. (See "Focal atrial tachycardia", section on 'Catheter ablation' and "Treatment of arrhythmias associated with the Wolff-Parkinson-White syndrome", section on 'Catheter ablation' and "Atrial tachyarrhythmias in children", section on 'Management' and "Atrioventricular nodal reentrant tachycardia", section on 'Catheter ablation'.)

Patients with frequent ectopy — For patients presenting with a high burden of premature ventricular complexes/contractions (PVCs) and newly recognized cardiomyopathy, initial management is to look for underlying causes (such as CAD, valvular heart disease, arrhythmogenic right ventricular dysplasia [ARVD], etc) and initiation of guideline-based optimal medical therapy for HF [100]. Correction of electrolytes and initiation of beta blockers are typical first therapies. (See "Overview of the management of heart failure with reduced ejection fraction in adults".)

Given the possibility of arrhythmia-induced cardiomyopathy in patients with a high PVC burden (eg, >15 to 20 percent of total beats on a 24-hour ambulatory monitor) and associated with LV dysfunction, we generally pursue radiofrequency catheter ablation [100-102]. Catheter ablation of high-frequency PVCs has emerged as a safe and effective therapy and may be considered if medical management is ineffective or poorly tolerated and depending on patient preference [59,74,103-105]. While it is not possible to specify an exact percentage (PVC burden) for which a patient might benefit from ablation of frequent PVCs as studies have had a wide range in their inclusion criteria, consideration may be given with a burden of above 10 percent, but our approach is typically to offer ablation at a higher burden (eg, >15 to 20 percent PVCs). The approach to catheter ablation in patients with a high PVC burden is discussed in greater detail separately. (See "Ventricular arrhythmias: Overview in patients with heart failure and cardiomyopathy" and "Premature ventricular complexes: Treatment and prognosis", section on 'Catheter ablation'.)

Patients with refractory tachyarrhythmias — In the event that a supraventricular arrhythmia is likely the cause of cardiomyopathy and cannot be primarily ablated, AV node ablation with either biventricular pacing or conduction system pacing is a reasonable approach to management.

While there are no studies that specifically address the strategy of AV nodal ablation and biventricular pacemaker placement in patients with arrhythmia-induced cardiomyopathy, there is indirect evidence to support this approach. In a trial that included patients with HF, a narrow QRS, and permanent AF but who did not explicitly have arrhythmia-induced cardiomyopathy, patients assigned to medical rate control had a higher risk of death or rehospitalization due to HF or worsening of HF when compared with patients assigned to AV node ablation and cardiac resynchronization therapy (38 versus 10 percent; hazard ratio 0.28, 95% CI 0.11-0.72) [106]. The effect of this approach on recovery of LVEF was not reported.

Other trials and studies of patients with preexisting AV node block, HF, and various causes of LV systolic dysfunction are discussed elsewhere. (See "Cardiac resynchronization therapy in heart failure: Indications and choice of system".)

FOLLOW-UP — Whereas the initial cardiomyopathy may have taken months to develop, recurrent tachycardia can lead to an abrupt decline in LVEF. Diastolic dysfunction can persist even after systolic function has normalized and can lead to decreased coronary flow reserve. In patients who develop a recurrence of the arrhythmia, the increased myocardial oxygen demand in the face of the decreased reserve can lead to redevelopment of cardiomyopathy [107,108]. As such, close ongoing monitoring with clinic visits, ambulatory (Holter) monitoring, and echocardiography are essential. Although there are minimal data and no society guidelines regarding the frequency of monitoring in these patients, we follow up with patients using a combination of clinic visits, echocardiography, and ambulatory monitoring every three to six months for one to two years following the initial clinical improvement.

The following is a typical follow-up schedule:

●Four to six weeks after initial presentation – Clinical follow-up, ECG.

●Three months after initial presentation – Clinical follow-up, ECG, echocardiogram, outpatient ambulatory monitor.

●Six months after initial presentation – Clinical follow-up, ECG.

●Twelve months after initial presentation – Clinical follow-up, ECG, echocardiogram, ECG, outpatient ambulatory monitor if symptoms suggest recurrence.

●Eighteen to 24 months after initial presentation – Clinical follow-up, ECG.

If complete recovery of EF is noted and angiotensin converting enzyme (ACE) inhibitors and beta blockers are tapered off, additional monitoring is required to be sure that EF remains normal [4].

PROGNOSIS — Following the restoration of sinus rhythm or ventricular rate control of the presenting tachycardia, most patients will have significant improvement and/or normalization of LVEF over a period of months. As such, patients who have not experienced sudden cardiac arrest or a sustained ventricular arrhythmia, and whose LVEF has improved to 40 percent or greater, usually do not require implantation of an implantable cardioverter-defibrillator (ICD). (See "Primary prevention of sudden cardiac death in patients with cardiomyopathy and heart failure with reduced LVEF".)

In some patients whose LVEF has normalized, the LV chamber may remain somewhat enlarged. Despite the apparent normalization of cardiac function when a tachycardia has been terminated or rate controlled, ultrastructural abnormalities of the myocardium may persist [60]. Additional evidence for persistent myocardial abnormality despite normalization of systolic function was seen in a study of successfully ablated patients with atrial tachycardia. These patients demonstrated LV structure and function changes including diffuse fibrosis on contrast-enhanced CMR imaging long after successful ablation (64±36 months) [90]. As noted previously, late-gadolinium enhancement on CMR suggests the presence of fibrosis and identifies irreversible structural changes that may predict incomplete recovery of LV function. For any patient whose LVEF fails to normalize with correction of the tachyarrhythmia, other underlying pathology should be considered including permanent structural changes [90,109]. If arrhythmia-induced cardiomyopathy recurs, these patients are at substantial risk for sudden death, and ICD implantation should be contemplated [107].

SOCIETY GUIDELINE LINKS — Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "Society guideline links: Arrhythmias in adults" and "Society guideline links: Ventricular arrhythmias" and "Society guideline links: Cardiac implantable electronic devices" and "Society guideline links: Supraventricular arrhythmias".)

INFORMATION FOR PATIENTS — UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)

●Beyond the Basics topics (see "Patient education: Atrial fibrillation (Beyond the Basics)" and "Patient education: Catheter ablation for abnormal heartbeats (Beyond the Basics)")

SUMMARY AND RECOMMENDATIONS

●Definition – Arrhythmia-induced cardiomyopathy is a relatively rare cause of a dilated cardiomyopathy resulting from prolonged periods of rapid ventricular heart rates. Arrhythmia-induced cardiomyopathy often improves or resolves following treatment and is associated with a good prognosis in most patients. (See 'Introduction' above.)

●Pathophysiology – Chronic tachycardia ultimately produces significant structural changes in the heart, with impressive left ventricular (LV) dilation and cellular morphologic changes leading to a cardiomyopathy. The precise mechanism(s) by which a chronic tachycardia produces these changes remain incompletely described. (See 'Pathophysiology' above.)

●Association with specific arrhythmias – Virtually all tachyarrhythmias have been reported to cause arrhythmia-induced cardiomyopathy, and frequent ectopic beats have also been associated with this condition. In most cases, the myocardial dysfunction improves or normalizes following therapy to control the ventricular heart rate or to restore normal sinus rhythm. (See 'Arrhythmias associated with arrhythmia-induced cardiomyopathy' above.)

●Clinical presentation – The clinical presentation of arrhythmia-induced cardiomyopathy is variable but usually involves signs and/or symptoms related to the tachyarrhythmia (eg, palpitations, dyspnea, chest discomfort, etc), heart failure (HF; eg, dyspnea, edema, weight gain, orthopnea, etc), or both. In our experience, HF symptoms are more common since patients with symptomatic tachyarrhythmias will frequently seek medical attention earlier in the course of their care and prior to the development of a cardiomyopathy. (See 'Clinical presentation' above.)

●ECG findings – All patients should have an ECG to document the cardiac rhythm and ventricular heart rate, with comparison to prior ECGs when available. There are no specific ECG findings that distinguish patients with and without arrhythmia-induced cardiomyopathy, and the ECG findings will vary depending upon the underlying tachyarrhythmia. (See 'ECG findings' above.)

●Approach to diagnosis – Arrhythmia-induced cardiomyopathy is defined by the presence of a sustained tachycardia (or frequent episodes of tachycardia or very frequent ectopy) that results in with LV systolic dysfunction. Usually the diagnosis of arrhythmia-induced cardiomyopathy can only be made following a successful trial of therapy to slow the ventricular rate or to restore sinus rhythm along with the exclusion of other potential causes of cardiomyopathy. Patients in whom arrhythmia-induced cardiomyopathy is suspected should undergo continuous cardiac monitoring for 24 to 48 hours and have non-invasive imaging to assess cardiac structure and function. For most patients, a transthoracic echocardiogram is the preferred test for assessing cardiac structure and function, although cardiovascular magnetic resonance (CMR) imaging is a reasonable alternative. (See 'Approach to the diagnosis' above and 'Diagnostic testing' above.)

●Treatment – The initial treatments for a patient with HF and suspected arrhythmia-induced cardiomyopathy are the same as those used in most other patients with HF (eg, angiotensin converting enzyme [ACE] inhibitors or angiotensin II receptor blockers [ARBs], beta blockers, diuretics) and tachyarrhythmias (eg, rate-control medications, consideration of antiarrhythmic drugs and/or cardioversion). However, because of the potential reversible nature of arrhythmia-induced cardiomyopathy, aggressive efforts should be made to achieve excellent ventricular heart rate control or to restore sinus rhythm. (See 'Treatment' above.)

•For minimally symptomatic patients with atrial fibrillation (AF) in whom adequate rate control is achieved, we continue medical therapy.

•For patients with AF who remain significantly symptomatic, or patients in whom adequate rate control is not achieved with medical therapy alone, we pursue a rhythm control strategy. (See "Management of atrial fibrillation: Rhythm control versus rate control" and "Atrial fibrillation: Cardioversion".)

•For patients with atrial flutter, rapid ventricular rates, and newly recognized depressed LV ejection fraction (LVEF), rate control may be difficult to achieve with medication. Because of this, we perform early electrical cardioversion in these patients. (See "Restoration of sinus rhythm in atrial flutter".)

•For supraventricular tachyarrhythmias (SVTs) other than AF or atrial flutter that result in arrhythmia-induced cardiomyopathy, restoration of sinus rhythm is the usual goal. The initial choice of modality (ie, electrical cardioversion, antiarrhythmic drugs, or catheter ablation of the arrhythmia) will vary depending upon the underlying SVT as well as the local expertise and availability of options.

•For patients presenting with a high burden of premature ventricular complexes/contractions (PVCs) and associated with LV dysfunction, we generally pursue radiofrequency catheter ablation.

•On rare occasions when all efforts at ventricular rate control, restoration of sinus rhythm, and catheter ablation of the arrhythmia have been unsuccessful for the treatment of SVTs, ablation of the AV node with insertion of a permanent pacemaker may be considered.

●Long-term monitoring – Close ongoing monitoring with clinic visits, ambulatory (Holter) monitoring, and echocardiography is essential to assess for any recurrence. We follow up with patients using a combination of clinic visits, echocardiography, and ambulatory monitoring every three to six months for one to two years following the initial clinical improvement. (See 'Follow-up' above.)

  1. Westphal JG, Rigopoulos AG, Bakogiannis C, et al. The MOGE(S) classification for cardiomyopathies: current status and future outlook. Heart Fail Rev 2017; 22:743.
  2. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Card Fail 2017; 23:628.
  3. Shinbane JS, Wood MA, Jensen DN, et al. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol 1997; 29:709.
  4. Gopinathannair R, Etheridge SP, Marchlinski FE, et al. Arrhythmia-Induced Cardiomyopathies: Mechanisms, Recognition, and Management. J Am Coll Cardiol 2015; 66:1714.
  5. Kasper EK, Agema WR, Hutchins GM, et al. The causes of dilated cardiomyopathy: a clinicopathologic review of 673 consecutive patients. J Am Coll Cardiol 1994; 23:586.
  6. SHACHNOW N, SPELLMAN S, RUBIN I. Persistent supraventricular tachycardia; case report with review of literature. Circulation 1954; 10:232.
  7. Engel TR, Bush CA, Schaal SF. Tachycardia-aggravated heart disease. Ann Intern Med 1974; 80:384.
  8. Coleman HN 3rd, Taylor RR, Pool PE, et al. Congestive heart failure following chronic tachycardia. Am Heart J 1971; 81:790.
  9. Vijgen J, Hill P, Biblo LA, Carlson MD. Tachycardia-induced cardiomyopathy secondary to right ventricular outflow tract ventricular tachycardia: improvement of left ventricular systolic function after radiofrequency catheter ablation of the arrhythmia. J Cardiovasc Electrophysiol 1997; 8:445.
  10. Singh B, Kaul U, Talwar KK, Wasir HS. Reversibility of "tachycardia induced cardiomyopathy" following the cure of idiopathic left ventricular tachycardia using radiofrequency energy. Pacing Clin Electrophysiol 1996; 19:1391.
  11. Baman TS, Lange DC, Ilg KJ, et al. Relationship between burden of premature ventricular complexes and left ventricular function. Heart Rhythm 2010; 7:865.
  12. Medi C, Kalman JM, Haqqani H, et al. Tachycardia-mediated cardiomyopathy secondary to focal atrial tachycardia: long-term outcome after catheter ablation. J Am Coll Cardiol 2009; 53:1791.
  13. Donghua Z, Jian P, Zhongbo X, et al. Reversal of cardiomyopathy in patients with congestive heart failure secondary to tachycardia. J Interv Card Electrophysiol 2013; 36:27.
  14. Brembilla-Perrot B, Ferreira JP, Manenti V, et al. Predictors and prognostic significance of tachycardiomyopathy: insights from a cohort of 1269 patients undergoing atrial flutter ablation. Eur J Heart Fail 2016; 18:394.
  15. Spinale FG, Hendrick DA, Crawford FA, et al. Chronic supraventricular tachycardia causes ventricular dysfunction and subendocardial injury in swine. Am J Physiol 1990; 259:H218.
  16. Howard RJ, Stopps TP, Moe GW, et al. Recovery from heart failure: structural and functional analysis in a canine model. Can J Physiol Pharmacol 1988; 66:1505.
  17. Morgan DE, Tomlinson CW, Qayumi AK, et al. Evaluation of ventricular contractility indexes in the dog with left ventricular dysfunction induced by rapid atrial pacing. J Am Coll Cardiol 1989; 14:489.
  18. Spinale FG, Tomita M, Zellner JL, et al. Collagen remodeling and changes in LV function during development and recovery from supraventricular tachycardia. Am J Physiol 1991; 261:H308.
  19. Kajstura J, Zhang X, Liu Y, et al. The cellular basis of pacing-induced dilated cardiomyopathy. Myocyte cell loss and myocyte cellular reactive hypertrophy. Circulation 1995; 92:2306.
  20. O'Brien PJ, Ianuzzo CD, Moe GW, et al. Rapid ventricular pacing of dogs to heart failure: biochemical and physiological studies. Can J Physiol Pharmacol 1990; 68:34.
  21. Ohno M, Cheng CP, Little WC. Mechanism of altered patterns of left ventricular filling during the development of congestive heart failure. Circulation 1994; 89:2241.
  22. Armstrong PW, Stopps TP, Ford SE, de Bold AJ. Rapid ventricular pacing in the dog: pathophysiologic studies of heart failure. Circulation 1986; 74:1075.
  23. Wilson JR, Douglas P, Hickey WF, et al. Experimental congestive heart failure produced by rapid ventricular pacing in the dog: cardiac effects. Circulation 1987; 75:857.
  24. Damiano RJ Jr, Tripp HF Jr, Asano T, et al. Left ventricular dysfunction and dilatation resulting from chronic supraventricular tachycardia. J Thorac Cardiovasc Surg 1987; 94:135.
  25. Yamamoto K, Burnett JC Jr, Meyer LM, et al. Ventricular remodeling during development and recovery from modified tachycardia-induced cardiomyopathy model. Am J Physiol 1996; 271:R1529.
  26. Huizar JF, Kaszala K, Potfay J, et al. Left ventricular systolic dysfunction induced by ventricular ectopy: a novel model for premature ventricular contraction-induced cardiomyopathy. Circ Arrhythm Electrophysiol 2011; 4:543.
  27. Pak PH, Nuss HB, Tunin RS, et al. Repolarization abnormalities, arrhythmia and sudden death in canine tachycardia-induced cardiomyopathy. J Am Coll Cardiol 1997; 30:576.
  28. Moe GW, Montgomery C, Howard RJ, et al. Left ventricular myocardial blood flow, metabolism, and effects of treatment with enalapril: further insights into the mechanisms of canine experimental pacing-induced heart failure. J Lab Clin Med 1993; 121:294.
  29. Spinale FG, Holzgrefe HH, Mukherjee R, et al. LV and myocyte structure and function after early recovery from tachycardia-induced cardiomyopathy. Am J Physiol 1995; 268:H836.
  30. Spinale FG, Clayton C, Tanaka R, et al. Myocardial Na+,K(+)-ATPase in tachycardia induced cardiomyopathy. J Mol Cell Cardiol 1992; 24:277.
  31. Kloner RA, DeBoer LW, Darsee JR, et al. Recovery from prolonged abnormalities of canine myocardium salvaged from ischemic necrosis by coronary reperfusion. Proc Natl Acad Sci U S A 1981; 78:7152.
  32. Reimer KA, Hill ML, Jennings RB. Prolonged depletion of ATP and of the adenine nucleotide pool due to delayed resynthesis of adenine nucleotides following reversible myocardial ischemic injury in dogs. J Mol Cell Cardiol 1981; 13:229.
  33. Spinale FG, Tanaka R, Crawford FA, Zile MR. Changes in myocardial blood flow during development of and recovery from tachycardia-induced cardiomyopathy. Circulation 1992; 85:717.
  34. Shannon RP, Komamura K, Shen YT, et al. Impaired regional subendocardial coronary flow reserve in conscious dogs with pacing-induced heart failure. Am J Physiol 1993; 265:H801.
  35. Perreault CL, Shannon RP, Komamura K, et al. Abnormalities in intracellular calcium regulation and contractile function in myocardium from dogs with pacing-induced heart failure. J Clin Invest 1992; 89:932.
  36. Tanaka R, Fulbright BM, Mukherjee R, et al. The cellular basis for the blunted response to beta-adrenergic stimulation in supraventricular tachycardia-induced cardiomyopathy. J Mol Cell Cardiol 1993; 25:1215.
  37. Sasayama S, Asanoi H, Ishizaka S. Continuous measurement of the pressure-volume relationship in experimental heart failure produced by rapid ventricular pacing in conscious dogs. Eur Heart J 1992; 13 Suppl E:47.
  38. Selby DE, Palmer BM, LeWinter MM, Meyer M. Tachycardia-induced diastolic dysfunction and resting tone in myocardium from patients with a normal ejection fraction. J Am Coll Cardiol 2011; 58:147.
  39. Marzo KP, Frey MJ, Wilson JR, et al. Beta-adrenergic receptor-G protein-adenylate cyclase complex in experimental canine congestive heart failure produced by rapid ventricular pacing. Circ Res 1991; 69:1546.
  40. Wakili R, Yeh YH, Yan Qi X, et al. Multiple potential molecular contributors to atrial hypocontractility caused by atrial tachycardia remodeling in dogs. Circ Arrhythm Electrophysiol 2010; 3:530.
  41. Yonemochi H, Yasunaga S, Teshima Y, et al. Rapid electrical stimulation of contraction reduces the density of beta-adrenergic receptors and responsiveness of cultured neonatal rat cardiomyocytes. Possible involvement of microtubule disassembly secondary to mechanical stress. Circulation 2000; 101:2625.
  42. Mihm MJ, Yu F, Carnes CA, et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 2001; 104:174.
  43. Shite J, Qin F, Mao W, et al. Antioxidant vitamins attenuate oxidative stress and cardiac dysfunction in tachycardia-induced cardiomyopathy. J Am Coll Cardiol 2001; 38:1734.
  44. Deshmukh PM, Krishnamani R, Romanyshyn M, et al. Association of angiotensin converting enzyme gene polymorphism with tachycardia cardiomyopathy. Int J Mol Med 2004; 13:455.
  45. Mueller KAL, Heinzmann D, Klingel K, et al. Reply: Histopathological and Immunological Characteristics of Tachycardia-Induced Cardiomyopathy. J Am Coll Cardiol 2017; 70:1687.
  46. Chiladakis JA, Vassilikos VP, Maounis TN, et al. Successful radiofrequency catheter ablation of automatic atrial tachycardia with regression of the cardiomyopathy picture. Pacing Clin Electrophysiol 1997; 20:953.
  47. Gillette PC, Smith RT, Garson A Jr, et al. Chronic supraventricular tachycardia. A curable cause of congestive cardiomyopathy. JAMA 1985; 253:391.
  48. Gallagher JJ. Tachycardia and cardiomyopathy: the chicken-egg dilemma revisited. J Am Coll Cardiol 1985; 6:1172.
  49. Bertil Olsson S, Blomström P, Sabel KG, William-Olsson G. Incessant ectopic atrial tachycardia: successful surgical treatment with regression of dilated cardiomyopathy picture. Am J Cardiol 1984; 53:1465.
  50. Packer DL, Bardy GH, Worley SJ, et al. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol 1986; 57:563.
  51. Rao PS, Najjar HN. Congestive cardiomyopathy due to chronic tachycardia: resolution of cardiomyopathy with antiarrhythmic drugs. Int J Cardiol 1987; 17:216.
  52. Gillette PC, Wampler DG, Garson A Jr, et al. Treatment of atrial automatic tachycardia by ablation procedures. J Am Coll Cardiol 1985; 6:405.
  53. Sanders P, Morton JB, Kistler PM, et al. Reversal of atrial mechanical dysfunction after cardioversion of atrial fibrillation: implications for the mechanisms of tachycardia-mediated atrial cardiomyopathy. Circulation 2003; 108:1976.
  54. Fishberger SB, Colan SD, Saul JP, et al. Myocardial mechanics before and after ablation of chronic tachycardia. Pacing Clin Electrophysiol 1996; 19:42.
  55. Aguinaga L, Primo J, Anguera I, et al. Long-term follow-up in patients with the permanent form of junctional reciprocating tachycardia treated with radiofrequency ablation. Pacing Clin Electrophysiol 1998; 21:2073.
  56. Leman RB, Gillette PC, Zinner AJ. Resolution of congestive cardiomyopathy caused by supraventricular tachycardia using amiodarone. Am Heart J 1986; 112:622.
  57. Corey WA, Markel ML, Hoit BD, Walsh RA. Regression of a dilated cardiomyopathy after radiofrequency ablation of incessant supraventricular tachycardia. Am Heart J 1993; 126:1469.
  58. Grimm W, Menz V, Hoffmann J, Maisch B. Reversal of tachycardia induced cardiomyopathy following ablation of repetitive monomorphic right ventricular outflow tract tachycardia. Pacing Clin Electrophysiol 2001; 24:166.
  59. Yarlagadda RK, Iwai S, Stein KM, et al. Reversal of cardiomyopathy in patients with repetitive monomorphic ventricular ectopy originating from the right ventricular outflow tract. Circulation 2005; 112:1092.
  60. Nerheim P, Birger-Botkin S, Piracha L, Olshansky B. Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation 2004; 110:247.
  61. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002; 113:359.
  62. Luchsinger JA, Steinberg JS. Resolution of cardiomyopathy after ablation of atrial flutter. J Am Coll Cardiol 1998; 32:205.
  63. Redfield MM, Kay GN, Jenkins LS, et al. Tachycardia-related cardiomyopathy: a common cause of ventricular dysfunction in patients with atrial fibrillation referred for atrioventricular ablation. Mayo Clin Proc 2000; 75:790.
  64. Edner M, Caidahl K, Bergfeldt L, et al. Prospective study of left ventricular function after radiofrequency ablation of atrioventricular junction in patients with atrial fibrillation. Br Heart J 1995; 74:261.
  65. Pizzale S, Lemery R, Green MS, et al. Frequency and predictors of tachycardia-induced cardiomyopathy in patients with persistent atrial flutter. Can J Cardiol 2009; 25:469.
  66. Hasdemir C, Ulucan C, Yavuzgil O, et al. Tachycardia-induced cardiomyopathy in patients with idiopathic ventricular arrhythmias: the incidence, clinical and electrophysiologic characteristics, and the predictors. J Cardiovasc Electrophysiol 2011; 22:663.
  67. Bogun F, Crawford T, Reich S, et al. Radiofrequency ablation of frequent, idiopathic premature ventricular complexes: comparison with a control group without intervention. Heart Rhythm 2007; 4:863.
  68. Yokokawa M, Kim HM, Good E, et al. Relation of symptoms and symptom duration to premature ventricular complex-induced cardiomyopathy. Heart Rhythm 2012; 9:92.
  69. Mountantonakis SE, Frankel DS, Gerstenfeld EP, et al. Reversal of outflow tract ventricular premature depolarization-induced cardiomyopathy with ablation: effect of residual arrhythmia burden and preexisting cardiomyopathy on outcome. Heart Rhythm 2011; 8:1608.
  70. Penela D, Van Huls Van Taxis C, Aguinaga L, et al. Neurohormonal, structural, and functional recovery pattern after premature ventricular complex ablation is independent of structural heart disease status in patients with depressed left ventricular ejection fraction: a prospective multicenter study. J Am Coll Cardiol 2013; 62:1195.
  71. El Kadri M, Yokokawa M, Labounty T, et al. Effect of ablation of frequent premature ventricular complexes on left ventricular function in patients with nonischemic cardiomyopathy. Heart Rhythm 2015; 12:706.
  72. Baser K, Bas HD, LaBounty T, et al. Recurrence of PVCs in patients with PVC-induced cardiomyopathy. Heart Rhythm 2015; 12:1519.
  73. Penela D, Acosta J, Aguinaga L, et al. Ablation of frequent PVC in patients meeting criteria for primary prevention ICD implant: Safety of withholding the implant. Heart Rhythm 2015; 12:2434.
  74. Laplante L, Benzaquen BS. A Review of the Potential Pathogenicity and Management of Frequent Premature Ventricular Contractions. Pacing Clin Electrophysiol 2016; 39:723.
  75. Lamba J, Redfearn DP, Michael KA, et al. Radiofrequency catheter ablation for the treatment of idiopathic premature ventricular contractions originating from the right ventricular outflow tract: a systematic review and meta-analysis. Pacing Clin Electrophysiol 2014; 37:73.
  76. Yokokawa M, Kim HM, Good E, et al. Impact of QRS duration of frequent premature ventricular complexes on the development of cardiomyopathy. Heart Rhythm 2012; 9:1460.
  77. Carballeira Pol L, Deyell MW, Frankel DS, et al. Ventricular premature depolarization QRS duration as a new marker of risk for the development of ventricular premature depolarization-induced cardiomyopathy. Heart Rhythm 2014; 11:299.
  78. Deyell MW, Park KM, Han Y, et al. Predictors of recovery of left ventricular dysfunction after ablation of frequent ventricular premature depolarizations. Heart Rhythm 2012; 9:1465.
  79. Yokokawa M, Good E, Crawford T, et al. Recovery from left ventricular dysfunction after ablation of frequent premature ventricular complexes. Heart Rhythm 2013; 10:172.
  80. Walters TE, Rahmutula D, Szilagyi J, et al. Left Ventricular Dyssynchrony Predicts the Cardiomyopathy Associated With Premature Ventricular Contractions. J Am Coll Cardiol 2018; 72:2870.
  81. Pacchia CF, Akoum NW, Wasmund S, Hamdan MH. Atrial bigeminy results in decreased left ventricular function: an insight into the mechanism of PVC-induced cardiomyopathy. Pacing Clin Electrophysiol 2012; 35:1232.
  82. Hasdemir C, Simsek E, Yuksel A. Premature atrial contraction-induced cardiomyopathy. Europace 2013; 15:1790.
  83. Arnold JM, Liu P, Demers C, et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol 2006; 22:23.
  84. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42:3599.
  85. Heart Failure Society of America, Lindenfeld J, Albert NM, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010; 16:e1.
  86. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2017; 136:e137.
  87. Sakaguchi H, Miyazaki A, Yamamoto M, et al. Clinical characteristics of focal atrial tachycardias arising from the atrial appendages during childhood. Pacing Clin Electrophysiol 2011; 34:177.
  88. Brugada J, Katritsis DG, Arbelo E, et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J 2020; 41:655.
  89. Jeong YH, Choi KJ, Song JM, et al. Diagnostic approach and treatment strategy in tachycardia-induced cardiomyopathy. Clin Cardiol 2008; 31:172.
  90. Ling LH, Kalman JM, Ellims AH, et al. Diffuse ventricular fibrosis is a late outcome of tachycardia-mediated cardiomyopathy after successful ablation. Circ Arrhythm Electrophysiol 2013; 6:697.
  91. Hasdemir C, Yuksel A, Camli D, et al. Late gadolinium enhancement CMR in patients with tachycardia-induced cardiomyopathy caused by idiopathic ventricular arrhythmias. Pacing Clin Electrophysiol 2012; 35:465.
  92. Kusunose K, Torii Y, Yamada H, et al. Clinical Utility of Longitudinal Strain to Predict Functional Recovery in Patients With Tachyarrhythmia and Reduced LVEF. JACC Cardiovasc Imaging 2017; 10:118.
  93. Ortiz-Genga M, García-Hernández S, Monserrat-Iglesias L, McKenna WJ. Preventing Sudden Death in Arrhythmogenic Cardiomyopathy: Careful Family and Genetic Evaluation Key to Appropriate Diagnosis and Management. Can J Cardiol 2021; 37:819.
  94. Ortiz-Genga MF, Cuenca S, Dal Ferro M, et al. Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies. J Am Coll Cardiol 2016; 68:2440.
  95. Grogan M, Smith HC, Gersh BJ, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992; 69:1570.
  96. Gentlesk PJ, Sauer WH, Gerstenfeld EP, et al. Reversal of left ventricular dysfunction following ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2007; 18:9.
  97. Manolis AG, Katsivas AG, Lazaris EE, et al. Ventricular performance and quality of life in patients who underwent radiofrequency AV junction ablation and permanent pacemaker implantation due to medically refractory atrial tachyarrhythmias. J Interv Card Electrophysiol 1998; 2:71.
  98. Prabhu S, Taylor AJ, Costello BT, et al. Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction: The CAMERA-MRI Study. J Am Coll Cardiol 2017; 70:1949.
  99. Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure: treatment considerations for a dual epidemic. Circulation 2009; 119:2516.
  100. Latchamsetty R, Bogun F. Premature Ventricular Complex-Induced Cardiomyopathy. JACC Clin Electrophysiol 2019; 5:537.
  101. Eugenio PL. Frequent Premature Ventricular Contractions: An Electrical Link to Cardiomyopathy. Cardiol Rev 2015; 23:168.
  102. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2018; 72:e91.
  103. Takemoto M, Yoshimura H, Ohba Y, et al. Radiofrequency catheter ablation of premature ventricular complexes from right ventricular outflow tract improves left ventricular dilation and clinical status in patients without structural heart disease. J Am Coll Cardiol 2005; 45:1259.
  104. Zhong L, Lee YH, Huang XM, et al. Relative efficacy of catheter ablation vs antiarrhythmic drugs in treating premature ventricular contractions: a single-center retrospective study. Heart Rhythm 2014; 11:187.
  105. Berruezo A, Penela D, Jáuregui B, et al. Mortality and morbidity reduction after frequent premature ventricular complexes ablation in patients with left ventricular systolic dysfunction. Europace 2019; 21:1079.
  106. Brignole M, Pokushalov E, Pentimalli F, et al. A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS. Eur Heart J 2018; 39:3999.
  107. Dandamudi G, Rampurwala AY, Mahenthiran J, et al. Persistent left ventricular dilatation in tachycardia-induced cardiomyopathy patients after appropriate treatment and normalization of ejection fraction. Heart Rhythm 2008; 5:1111.
  108. Moe GW, Armstrong P. Pacing-induced heart failure: a model to study the mechanism of disease progression and novel therapy in heart failure. Cardiovasc Res 1999; 42:591.
  109. Ling LH, Taylor AJ, Ellims AH, et al. Sinus rhythm restores ventricular function in patients with cardiomyopathy and no late gadolinium enhancement on cardiac magnetic resonance imaging who undergo catheter ablation for atrial fibrillation. Heart Rhythm 2013; 10:1334.
Topic 1062 Version 48.0

References

1 : The MOGE(S) classification for cardiomyopathies: current status and future outlook.

2 : 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.

3 : Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies.

4 : Arrhythmia-Induced Cardiomyopathies: Mechanisms, Recognition, and Management.

5 : The causes of dilated cardiomyopathy: a clinicopathologic review of 673 consecutive patients.

6 : Persistent supraventricular tachycardia; case report with review of literature.

7 : Tachycardia-aggravated heart disease.

8 : Congestive heart failure following chronic tachycardia.

9 : Tachycardia-induced cardiomyopathy secondary to right ventricular outflow tract ventricular tachycardia: improvement of left ventricular systolic function after radiofrequency catheter ablation of the arrhythmia.

10 : Reversibility of "tachycardia induced cardiomyopathy" following the cure of idiopathic left ventricular tachycardia using radiofrequency energy.

11 : Relationship between burden of premature ventricular complexes and left ventricular function.

12 : Tachycardia-mediated cardiomyopathy secondary to focal atrial tachycardia: long-term outcome after catheter ablation.

13 : Reversal of cardiomyopathy in patients with congestive heart failure secondary to tachycardia.

14 : Predictors and prognostic significance of tachycardiomyopathy: insights from a cohort of 1269 patients undergoing atrial flutter ablation.

15 : Chronic supraventricular tachycardia causes ventricular dysfunction and subendocardial injury in swine.

16 : Recovery from heart failure: structural and functional analysis in a canine model.

17 : Evaluation of ventricular contractility indexes in the dog with left ventricular dysfunction induced by rapid atrial pacing.

18 : Collagen remodeling and changes in LV function during development and recovery from supraventricular tachycardia.

19 : The cellular basis of pacing-induced dilated cardiomyopathy. Myocyte cell loss and myocyte cellular reactive hypertrophy.

20 : Rapid ventricular pacing of dogs to heart failure: biochemical and physiological studies.

21 : Mechanism of altered patterns of left ventricular filling during the development of congestive heart failure.

22 : Rapid ventricular pacing in the dog: pathophysiologic studies of heart failure.

23 : Experimental congestive heart failure produced by rapid ventricular pacing in the dog: cardiac effects.

24 : Left ventricular dysfunction and dilatation resulting from chronic supraventricular tachycardia.

25 : Ventricular remodeling during development and recovery from modified tachycardia-induced cardiomyopathy model.

26 : Left ventricular systolic dysfunction induced by ventricular ectopy: a novel model for premature ventricular contraction-induced cardiomyopathy.

27 : Repolarization abnormalities, arrhythmia and sudden death in canine tachycardia-induced cardiomyopathy.

28 : Left ventricular myocardial blood flow, metabolism, and effects of treatment with enalapril: further insights into the mechanisms of canine experimental pacing-induced heart failure.

29 : LV and myocyte structure and function after early recovery from tachycardia-induced cardiomyopathy.

30 : Myocardial Na+,K(+)-ATPase in tachycardia induced cardiomyopathy.

31 : Recovery from prolonged abnormalities of canine myocardium salvaged from ischemic necrosis by coronary reperfusion.

32 : Prolonged depletion of ATP and of the adenine nucleotide pool due to delayed resynthesis of adenine nucleotides following reversible myocardial ischemic injury in dogs.

33 : Changes in myocardial blood flow during development of and recovery from tachycardia-induced cardiomyopathy.

34 : Impaired regional subendocardial coronary flow reserve in conscious dogs with pacing-induced heart failure.

35 : Abnormalities in intracellular calcium regulation and contractile function in myocardium from dogs with pacing-induced heart failure.

36 : The cellular basis for the blunted response to beta-adrenergic stimulation in supraventricular tachycardia-induced cardiomyopathy.

37 : Continuous measurement of the pressure-volume relationship in experimental heart failure produced by rapid ventricular pacing in conscious dogs.

38 : Tachycardia-induced diastolic dysfunction and resting tone in myocardium from patients with a normal ejection fraction.

39 : Beta-adrenergic receptor-G protein-adenylate cyclase complex in experimental canine congestive heart failure produced by rapid ventricular pacing.

40 : Multiple potential molecular contributors to atrial hypocontractility caused by atrial tachycardia remodeling in dogs.

41 : Rapid electrical stimulation of contraction reduces the density of beta-adrenergic receptors and responsiveness of cultured neonatal rat cardiomyocytes. Possible involvement of microtubule disassembly secondary to mechanical stress.

42 : Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation.

43 : Antioxidant vitamins attenuate oxidative stress and cardiac dysfunction in tachycardia-induced cardiomyopathy.

44 : Association of angiotensin converting enzyme gene polymorphism with tachycardia cardiomyopathy.

45 : Reply: Histopathological and Immunological Characteristics of Tachycardia-Induced Cardiomyopathy.

46 : Successful radiofrequency catheter ablation of automatic atrial tachycardia with regression of the cardiomyopathy picture.

47 : Chronic supraventricular tachycardia. A curable cause of congestive cardiomyopathy.

48 : Tachycardia and cardiomyopathy: the chicken-egg dilemma revisited.

49 : Incessant ectopic atrial tachycardia: successful surgical treatment with regression of dilated cardiomyopathy picture.

50 : Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction.

51 : Congestive cardiomyopathy due to chronic tachycardia: resolution of cardiomyopathy with antiarrhythmic drugs.

52 : Treatment of atrial automatic tachycardia by ablation procedures.

53 : Reversal of atrial mechanical dysfunction after cardioversion of atrial fibrillation: implications for the mechanisms of tachycardia-mediated atrial cardiomyopathy.

54 : Myocardial mechanics before and after ablation of chronic tachycardia.

55 : Long-term follow-up in patients with the permanent form of junctional reciprocating tachycardia treated with radiofrequency ablation.

56 : Resolution of congestive cardiomyopathy caused by supraventricular tachycardia using amiodarone.

57 : Regression of a dilated cardiomyopathy after radiofrequency ablation of incessant supraventricular tachycardia.

58 : Reversal of tachycardia induced cardiomyopathy following ablation of repetitive monomorphic right ventricular outflow tract tachycardia.

59 : Reversal of cardiomyopathy in patients with repetitive monomorphic ventricular ectopy originating from the right ventricular outflow tract.

60 : Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia.

61 : A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study.

62 : Resolution of cardiomyopathy after ablation of atrial flutter.

63 : Tachycardia-related cardiomyopathy: a common cause of ventricular dysfunction in patients with atrial fibrillation referred for atrioventricular ablation.

64 : Prospective study of left ventricular function after radiofrequency ablation of atrioventricular junction in patients with atrial fibrillation.

65 : Frequency and predictors of tachycardia-induced cardiomyopathy in patients with persistent atrial flutter.

66 : Tachycardia-induced cardiomyopathy in patients with idiopathic ventricular arrhythmias: the incidence, clinical and electrophysiologic characteristics, and the predictors.

67 : Radiofrequency ablation of frequent, idiopathic premature ventricular complexes: comparison with a control group without intervention.

68 : Relation of symptoms and symptom duration to premature ventricular complex-induced cardiomyopathy.

69 : Reversal of outflow tract ventricular premature depolarization-induced cardiomyopathy with ablation: effect of residual arrhythmia burden and preexisting cardiomyopathy on outcome.

70 : Neurohormonal, structural, and functional recovery pattern after premature ventricular complex ablation is independent of structural heart disease status in patients with depressed left ventricular ejection fraction: a prospective multicenter study.

71 : Effect of ablation of frequent premature ventricular complexes on left ventricular function in patients with nonischemic cardiomyopathy.

72 : Recurrence of PVCs in patients with PVC-induced cardiomyopathy.

73 : Ablation of frequent PVC in patients meeting criteria for primary prevention ICD implant: Safety of withholding the implant.

74 : A Review of the Potential Pathogenicity and Management of Frequent Premature Ventricular Contractions.

75 : Radiofrequency catheter ablation for the treatment of idiopathic premature ventricular contractions originating from the right ventricular outflow tract: a systematic review and meta-analysis.

76 : Impact of QRS duration of frequent premature ventricular complexes on the development of cardiomyopathy.

77 : Ventricular premature depolarization QRS duration as a new marker of risk for the development of ventricular premature depolarization-induced cardiomyopathy.

78 : Predictors of recovery of left ventricular dysfunction after ablation of frequent ventricular premature depolarizations.

79 : Recovery from left ventricular dysfunction after ablation of frequent premature ventricular complexes.

80 : Left Ventricular Dyssynchrony Predicts the Cardiomyopathy Associated With Premature Ventricular Contractions.

81 : Atrial bigeminy results in decreased left ventricular function: an insight into the mechanism of PVC-induced cardiomyopathy.

82 : Premature atrial contraction-induced cardiomyopathy.

83 : Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management.

84 : 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.

85 : HFSA 2010 Comprehensive Heart Failure Practice Guideline.

86 : 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.

87 : Clinical characteristics of focal atrial tachycardias arising from the atrial appendages during childhood.

88 : 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC).

89 : Diagnostic approach and treatment strategy in tachycardia-induced cardiomyopathy.

90 : Diffuse ventricular fibrosis is a late outcome of tachycardia-mediated cardiomyopathy after successful ablation.

91 : Late gadolinium enhancement CMR in patients with tachycardia-induced cardiomyopathy caused by idiopathic ventricular arrhythmias.

92 : Clinical Utility of Longitudinal Strain to Predict Functional Recovery in Patients With Tachyarrhythmia and Reduced LVEF.

93 : Preventing Sudden Death in Arrhythmogenic Cardiomyopathy: Careful Family and Genetic Evaluation Key to Appropriate Diagnosis and Management.

94 : Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies.

95 : Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy.

96 : Reversal of left ventricular dysfunction following ablation of atrial fibrillation.

97 : Ventricular performance and quality of life in patients who underwent radiofrequency AV junction ablation and permanent pacemaker implantation due to medically refractory atrial tachyarrhythmias.

98 : Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction: The CAMERA-MRI Study.

99 : Atrial fibrillation and heart failure: treatment considerations for a dual epidemic.

100 : Premature Ventricular Complex-Induced Cardiomyopathy.

101 : Frequent Premature Ventricular Contractions: An Electrical Link to Cardiomyopathy.

102 : 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.

103 : Radiofrequency catheter ablation of premature ventricular complexes from right ventricular outflow tract improves left ventricular dilation and clinical status in patients without structural heart disease.

104 : Relative efficacy of catheter ablation vs antiarrhythmic drugs in treating premature ventricular contractions: a single-center retrospective study.

105 : Mortality and morbidity reduction after frequent premature ventricular complexes ablation in patients with left ventricular systolic dysfunction.

106 : A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS.

107 : Persistent left ventricular dilatation in tachycardia-induced cardiomyopathy patients after appropriate treatment and normalization of ejection fraction.

108 : Pacing-induced heart failure: a model to study the mechanism of disease progression and novel therapy in heart failure.

109 : Sinus rhythm restores ventricular function in patients with cardiomyopathy and no late gadolinium enhancement on cardiac magnetic resonance imaging who undergo catheter ablation for atrial fibrillation.

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟